Milestone Scientific Inc.MLSS

Milestone Scientific Inc. (MLSS) reported a net loss of $839,853 and operating loss of $828,083 in Q1 2026, with cash reserves of just $1.2M against liabilities of $5.7M, according to its latest 10-Q filing. The company, which develops medical devices including its DPS Dynamic Pressure Sensing anesthetic delivery system, holds $3.5M in inventory-more than its total equity of $2.3M-raising questions about demand and liquidity.

MLSS’s financial strain contrasts with its promotional narrative of technological leadership. While the company highlights CE approval for its device and aims to establish it as a 'standard-of-care,' its research and development expenses fell to $369k in FY2025 (from prior periods), and it recorded negative operating cash flow of $86k in Q1. The recent dismissal of auditor PwC, disclosed in a May 6, 2026, 8-K filing, adds regulatory scrutiny to its challenges.

The company’s DEF 14A and PRE 14A filings repeatedly direct readers to its website for governance documents, a practice that feels less like transparency and more like a deflection tactic given the financials. With a diluted EPS of -$0.01 and 85M shares outstanding, MLSS’s ability to fund operations beyond late 2026 hinges on raising capital-a prospect that could dilute shareholders further or require asset sales.

Inventory levels remain a critical risk: despite a $290k reduction in Q1, MLSS still holds 44% of its total assets in stock, suggesting either overoptimism about sales or underinvestment in working capital management. The company’s cash burn and lack of positive free cash flow ($86k from operations barely offsetting $1.6k in capex) leave little room for error in its go-to-market strategy.